Viewing Study NCT00250120



Ignite Creation Date: 2024-05-05 @ 12:09 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00250120
Status: WITHDRAWN
Last Update Posted: 2016-05-12
First Post: 2005-11-03

Brief Title: Pharmacology Study of Aerosolized Liposomal
Sponsor: University of New Mexico
Organization: University of New Mexico

Study Overview

Official Title: Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 S - Camptothecin L9NC
Status: WITHDRAWN
Status Verified Date: 2016-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To determine the overall response rate to liposomal 9-Nitro-20 S-Camptothecin L9NC administered by aerosolization in patients with non-small-cell lung cancer any stage

To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks every 10 weeks

To perform a pharmacology study of L9NC in the plasma and the lungs after aerosolization A specific protocol will be written for this part
Detailed Description: This is a single-arm non-randomized Phase II trial of DLPC-9NC administered by aerosol 5 consecutive days per week for 8 weeks every 10 weeks

Dose 04 mgml of 9-NC in aerosol reservoir for 60 minutes daily dose of 052 mgm2day per day X5 every week X8 weeks then observe for 2 weeks One course 10 weeks

Patients that have a resectable lung cancer will only receive one course of treatment and will be operated on about two weeks after completing the 8-week course

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None